Hurd,Yasmin, Ph.D.

Quick facts

Phase 2 pipeline

• Cannabidiol 400 · Neurology
  Cannabidiol 400 acts as a cannabinoid receptor agonist, modulating the endocannabinoid system to exert therapeutic effects.
• Cannabidiol 800

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Hurd,Yasmin, Ph.D. portfolio CI brief
• Hurd,Yasmin, Ph.D. pipeline updates RSS

Related

• Sector hub: All tracked pharma companies